Morningstar

Intellia Therapeutics Inc NTLA

Morningstar Rating
Unlock
Stock XNAS Rating as of
$18.55 −0.65 (3.39%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Intellia's Gene Editing Pipeline Looks Promising for Long-Term Investors With High Risk Tolerance

Rachel Elfman

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr/Cas9 has created a new class of medicines, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Read Full Report

Price vs Fair Value

View History
NTLA is trading at a 291% premium.
Price
$18.55
Fair Value
$91.00
Uncertainty
Very High
1-Star Price
$258.86
5-Star Price
$46.20
Economic Moat
Wytq
Capital Allocation
Ftmpqpp

Bulls Say, Bears Say

Bulls

Intellia's partnerships allow it to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

Intellia's pipeline is largely in the early stages of development and several years away from potentially receiving approval.

Show More

News

View All

Trading Information

Previous Close Price
$19.20
Day Range
$18.53–19.11
52-Week Range
$18.53–34.87
Bid/Ask
$18.57 / $18.65
Market Cap
$1.88 Bil
Volume/Avg
1.8 Mil / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
35.99
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
598
Website
https://www.intelliatx.com

Competitors

Valuation

View More
Metric
NTLA
MRNA
CRSP
Price/Earnings (Normalized)
 ———
Price/Book Value
 1.882.071.96
Price/Sales
 35.994.8318.61
Price/Cash Flow
 ———
Price/Earnings
NTLA
MRNA
CRSP

Financial Strength

Metric
NTLA
MRNA
CRSP
Quick Ratio
 6.693.770.00
Current Ratio
 7.214.0915.73
Interest Coverage
 —−169.39—
Quick Ratio
NTLA
MRNA
CRSP

Profitability

Metric
NTLA
MRNA
CRSP
Return on Assets (Normalized)
 −28.75%−29.83%−8.47%
Return on Equity (Normalized)
 −34.94%−39.97%−10.08%
Return on Invested Capital (Normalized)
 −35.82%−38.74%−9.15%
Return on Assets
NTLA
MRNA
CRSP

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
JrvwkdllPgbp$518.0 Bil
 Vertex Pharmaceuticals Inc
VRTX
KxdlxrcbZzyzwm$119.3 Bil
 Regeneron Pharmaceuticals Inc
REGN
PcbmbkmyPwjxpnk$114.7 Bil
 Alnylam Pharmaceuticals Inc
ALNY
PpzsywcgLmhtvsg$34.9 Bil
 argenx SE ADR
ARGX
TpjfqhxrjYpf$32.9 Bil
 BioNTech SE ADR
BNTX
MbrxxkjpTdfjx$28.3 Bil
 Moderna Inc
MRNA
TwbcjlrdrBjr$24.3 Bil
 United Therapeutics Corp
UTHR
DygztrgzKddf$15.7 Bil
 Biomarin Pharmaceutical Inc
BMRN
LbrvgwknMnhdbt$13.3 Bil
 Incyte Corp
INCY
JfbnwrpvpJtbfqd$13.0 Bil

Sponsor Center